Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 31, 2005 Karl Thiel	Is Eyetech Better Than It Looks? If you're a born contrarian with a little spare mad money lying around, this biotech could be worth buying at these levels.
The Motley Fool March 31, 2008 Brian Lawler	A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration.
The Motley Fool October 2, 2007 Brian Orelli	Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data.
The Motley Fool August 22, 2005 Rich Duprey	Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies.
The Motley Fool October 26, 2006 Brian Lawler	QLT Quickly Losing Traction The biotech company gets hammered by a competitor's superior product. There was one bright spot in the quarter for QLT, though. Investors, take note.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool January 3, 2005 Rich Duprey	Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA.
The Motley Fool October 29, 2007 Brian Lawler	QLT in a Rut or Ready for a Comeback? QLT updates investors on its top drugs.
Chemistry World May 9, 2011 Andrew Turley	New data reignites eye drug debate Interim results from a much anticipated comparative study of two drugs support what many ophthalmologists already believe: that ranibizumab and bevacizumab are equally good for the treatment of neovascular age related macular degeneration.
The Motley Fool July 5, 2006 Brian Lawler	Stay Away From QLT Competitive pressure on its top drug makes this company one investors should avoid.
The Motley Fool January 22, 2007 Brian Lawler	QLT's Sagging Sales The drug developer's macular degeneration treatment has seen declining sales. And as sales fall, so too does the percent of profits that QLT keeps. Investors, take note.
The Motley Fool October 26, 2004 Charly Travers	Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point.
The Motley Fool August 31, 2004 Charly Travers	Hidden Value With QLT The market might overlook the drug maker's promising programs. Over the next six months, biotech investors should keep an eye on this one.
The Motley Fool July 17, 2007 Brian Lawler	QLT Stays the Course Sales of QLT's Visudyne, a drug to treat macular degeneration, continue to plummet due to competition. QLT plans to try to resuscitate.
The Motley Fool January 21, 2005 Charly Travers	Seeing the Value in QLT A narrow-minded market could be creating a great drug value.
The Motley Fool November 19, 2011 Luke Timmerman	Regeneron Wins FDA Approval for Macular-Degeneration Drug The company can begin selling Eylea, which treats the leading cause of blindness in the elderly.
BusinessWeek August 16, 2004 Arlene Weintraub	The Race to Stop an Eyesight Stealer No magic bullet yet, but new drugs to fight age-related macular degeneration are near.
Chemistry World January 13, 2011 Andrew Turley	UK tilts towards appraisal of Avastin as eye drug The UK is moving closer to opening up the National Health Service to cancer drug Avastin (bevacizumab) for the treatment of eye conditions, such as age-related macular degeneration.
The Motley Fool November 23, 2010 Brian Orelli	Less of a Poke in the Eye Regeneron Pharmaceuticals was up nearly 20% yesterday after the drugmaker announced the results for two phase 3 trials testing VEGF Trap-Eye in wet AMD patients.
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
The Motley Fool April 24, 2007 Brian Lawler	Is the Worst Over for QLT? The biopharma announces another dismal quarter of declining sales for its top compound.
Chemistry World September 24, 2014 Phillip Broadwith	Review says cheaper drug is safe for eye disease Researchers have added weight to the argument that health services should use the cancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration, instead of the more expensive Lucentis (ranibizumab).
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
The Motley Fool January 5, 2005 Rich Duprey	Sharks Don't Go Blind Shark liver oil shows promise in treatment of age-related macular degeneration. Genaera Corp. though leading this interesting investigation, is not profitable, racking up some significant losses over the years.
Managed Care August 2006 Thomas Morrow	New Injectable Medication Effective Against Wet AMD Age-related macular degeneration is the most common cause of blindness in people over age 55. This market will expand rapidly. Managed care should remain informed and start to manage this area.
The Motley Fool August 21, 2008 Brian Lawler	Regeneron's Results Clearing Up The drugmaker presents new data on a compelling candidate for macular degeneration treatment.
Managed Care March 2005 Thomas Morrow	Aptamers: Slowing Progression of AMD A single strand of nucleic acid may hold the key to treating the leading cause of severe vision loss and blindness resulting from age-related macular degeneration.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
The Motley Fool October 11, 2005 Stephen D. Simpson	Genentech Generates Profits Whether you call it a biotech or a pharmaceutical, there's no disputing that Genentech is raking in some big bucks. Trying to value this stock is no treat, but growth-oriented investors should still have much to look forward to over the years.
The Motley Fool March 29, 2005 Charly Travers	A Biotech Value Play Sometimes you have to invest against the grain. Take a look at Canadian drug company QLT.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
Chemistry World April 2, 2015 Emma Stoye	Novartis accused of 'derailing' trials for cheap eye disease drug The British Medical Journal has accused pharmaceutical giant Novartis of deliberately hindering research into the use of anticancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration.
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
The Motley Fool November 29, 2007 Brian Lawler	QLT Goes on the Block QLT announced yesterday that it's in the preliminary stages of exploring a sale.
The Motley Fool July 12, 2005 Charly Travers	Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
The Motley Fool November 25, 2008 Brian Orelli	Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
Chemistry World May 21, 2014 Phillip Broadwith	Novartis enhances its focus with eyecare deal Swiss pharma major Novartis is continuing its quest to excel in a few specialist fields by licensing rights to US firm Ophthotech's lead candidate, Fovista, for wet age-related macular degeneration.
The Motley Fool November 22, 2006 Brian Lawler	How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
The Motley Fool April 25, 2005 Charly Travers	Where Is QLT going? The drug maker's upcoming conference call needs to address the question. Shares are down 30% since the beginning of the year. Can QLT turn this around?
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool June 21, 2005 Brian Gorman	Genentech Hedges Its Edge The company's manufacturing capacity may allow it to attract biotech partners for years into the future. Investors, take note.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool November 17, 2006 Brian Lawler	Genentech Gets Another Approval Today, Genentech finally received formal approval to market its breast cancer therapy Herceptin for the early stages. Investors, take note.